Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06038578 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 4 months later Jun 30, 2026 → Oct 31, 2027
See other at-risk trials from Toray Industries, Inc

Record History

  1. Primary and study completion pushed from Jun 30, 2026 to Oct 31, 2027 Eligibility criteria expanded, about 34 words · Secondary endpoints: details revised at 2 of 27 entries · Publications: details revised at 1 of 1 entry Show 3 more changesShow less
    • Eligibility criteria expanded, about 34 words
    • Secondary endpoints: details revised at 2 of 27 entries
    • Publications: details revised at 1 of 1 entry
  2. 2 versions Re-verified since Jul 30, 2025, no change to tracked fieldsv20-v21
  3. Study sites: 26 to 27v19
  4. Study sites: 23 to 26v18
  5. Study sites: 22 to 23v17
Show 15 earlier versionsHide 15 earlier versions
  1. Study sites: 21 to 22v16
  2. Site contacts updated at 7 of 21 sitesv15
  3. Study sites: 11 to 21v14
  4. Primary and study completion dates: Aug 31, 2025 to Jun 30, 2026 Site contacts updated at 1 of 11 sitesv13 Show 1 more changeShow less
    • Site contacts updated at 1 of 11 sites
  5. Re-verified, no change to tracked fieldsv12
  6. Study sites: 10 to 11v11
  7. Study sites: 7 to 10 Eligibility criteria expanded, about 173 wordsv10 Show 1 more changeShow less
    • Eligibility criteria expanded, about 173 words

    See this version in full on ClinicalTrials.gov ↗

  8. Site details revised at 1 of 7 sitesv9
  9. Study sites: 4 to 7v8
  10. Study sites: 2 to 4v7
  11. Study sites revised (2)v6 See this version in full on ClinicalTrials.gov ↗
  12. Study sites revised (2)v5 See this version in full on ClinicalTrials.gov ↗
  13. Start date changed from estimate of Sep 2023 to Oct 4, 2023v4
  14. Trial status: Not Yet Recruiting to Recruiting Study sites: 1 to 2 · Start date: Sep 27, 2023 to Sep 2023v3 Show 2 more changesShow less
    • Study sites: 1 to 2
    • Start date: Sep 27, 2023 to Sep 2023
  15. Study title shortened, about 2 wordsv2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will assess the efficacy, safety, optimal dose and ADA and NAbs development of TRK-950 at two separate dose levels in combination with ramucirumab and paclitaxel (RAM+PTX) as compared with RAM + PTX treatment alone in participants with gastric or gastro-esophageal junction (GEJ) adenocarcinoma.
Trial Details
NCT Number NCT06038578
Lead Sponsor Toray Industries, Inc
Conditions Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Enrollment 146 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov